253 related articles for article (PubMed ID: 32576165)
1. DNA methylation signatures of Prostate Cancer in peripheral T-cells.
Mehdi A; Cheishvili D; Arakelian A; Bismar TA; Szyf M; Rabbani SA
BMC Cancer; 2020 Jun; 20(1):588. PubMed ID: 32576165
[TBL] [Abstract][Full Text] [Related]
2. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation signatures of breast cancer in peripheral T-cells.
Parashar S; Cheishvili D; Mahmood N; Arakelian A; Tanvir I; Khan HA; Kremer R; Mihalcioiu C; Szyf M; Rabbani SA
BMC Cancer; 2018 May; 18(1):574. PubMed ID: 29776342
[TBL] [Abstract][Full Text] [Related]
4. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
5. Evaluating liquid biopsies for methylomic profiling of prostate cancer.
Silva R; Moran B; Russell NM; Fahey C; Vlajnic T; Manecksha RP; Finn SP; Brennan DJ; Gallagher WM; Perry AS
Epigenetics; 2020; 15(6-7):715-727. PubMed ID: 32000564
[TBL] [Abstract][Full Text] [Related]
6. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
7. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
8. Epigenome-Wide Association Study of Prostate Cancer in African Americans Identifies DNA Methylation Biomarkers for Aggressive Disease.
Xu Y; Tsai CW; Chang WS; Han Y; Huang M; Pettaway CA; Bau DT; Gu J
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944472
[TBL] [Abstract][Full Text] [Related]
9. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
[TBL] [Abstract][Full Text] [Related]
10. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
[TBL] [Abstract][Full Text] [Related]
11. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
12. Differential DNA Methylation in Prostate Tumors from Puerto Rican Men.
Ruiz-Deya G; Matta J; Encarnación-Medina J; Ortiz-Sanchéz C; Dutil J; Putney R; Berglund A; Dhillon J; Kim Y; Park JY
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450964
[TBL] [Abstract][Full Text] [Related]
13. Epigenome-wide DNA methylation profiling of periprostatic adipose tissue in prostate cancer patients with excess adiposity-a pilot study.
Cheng Y; Monteiro C; Matos A; You J; Fraga A; Pereira C; Catalán V; Rodríguez A; Gómez-Ambrosi J; Frühbeck G; Ribeiro R; Hu P
Clin Epigenetics; 2018; 10():54. PubMed ID: 29692867
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic risk score improves prostate cancer risk assessment.
Van Neste L; Groskopf J; Grizzle WE; Adams GW; DeGuenther MS; Kolettis PN; Bryant JE; Kearney GP; Kearney MC; Van Criekinge W; Gaston SM
Prostate; 2017 Sep; 77(12):1259-1264. PubMed ID: 28762545
[TBL] [Abstract][Full Text] [Related]
17. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
18. Relationships among Immune Score, TCF21 Methylation, Risk-factor Level, and Prognosis in Prostate Cancer.
Zhang W; Huang Z; Xin J
J Coll Physicians Surg Pak; 2022 Mar; 32(3):319-323. PubMed ID: 35148583
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
20. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.
Yang B; Etheridge T; McCormick J; Schultz A; Khemees TA; Damaschke N; Leverson G; Woo K; Sonn GA; Klein EA; Fumo M; Huang W; Jarrard DF
Clin Epigenetics; 2019 Nov; 11(1):168. PubMed ID: 31779677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
